AIM This executive summary of the valvular heart disease guideline provides recommendations for clinicians to diagnose and manage valvular heart disease as well as supporting documentation to encourage their use. METHODS A comprehensive literature search was conducted from January 1, 2010, to March 1, 2020, encompassing studies, reviews, and other evidence conducted on human subjects that were published in English from PubMed, EMBASE, Cochrane, Agency for Healthcare Research and Quality Reports, and other selected database relevant to this guideline. STRUCTURE Many recommendations from the earlier valvular heart disease guidelines have been updated with new evidence and provides newer options for diagnosis and treatment of valvular heart disease. This summary includes only the recommendations from the full guideline which focus on diagnostic work-up, the timing and choice of surgical and catheter interventions, and recommendations for medical therapy. The reader is referred to the full guideline for graphical flow charts, text, and tables with additional details about the rationale for and implementation of each recommendation, and the evidence tables detailing the data considered in developing these guidelines.

中文翻译：

---

2020 年 ACC/AHA 心脏瓣膜病患者管理指南：执行摘要

目的 本瓣膜性心脏病指南的执行摘要为临床医生诊断和管理瓣膜性心脏病提供了建议，并提供了鼓励使用的支持文件。方法 对 2010 年 1 月 1 日至 2020 年 3 月 1 日进行了全面的文献检索，包括在 PubMed、EMBASE、Cochrane、医疗保健研究和质量报告机构以英文发表的人类受试者的研究、评论和其他证据，以及与本指南相关的其他选定数据库。结构 早期心脏瓣膜病指南中的许多建议已根据新证据进行了更新，并为瓣膜性心脏病的诊断和治疗提供了更新的选择。本摘要仅包括完整指南中的建议，这些建议侧重于诊断检查、手术和导管干预的时机和选择，以及药物治疗的建议。读者可以参考完整指南的图形流程图、文本和表格，其中包含有关每项建议的基本原理和实施的更多详细信息，以及详细说明制定这些指南时考虑的数据的证据表。